Modulation of prepulse inhibition and stereotypies in rodents: No evidence for antipsychotic-like properties of histamine H 3-receptor inverse agonists

Psychopharmacology

Volumn 210, Issue 4, 2010, Pages 591-604

  Burban, Aude ^a   Sadakhom, Chit ^a   Dumoulin, Dominique ^a   Rose, Christiane ^a   Pen, Gwenaëlle Le ^a   Frances, Henriette ^a   Arrang, Jean Michel ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Apomorphine; H 3 receptor inverse agonist; Histamine; Methamphetamine; MK 801; Phencyclidine; Prepulse inhibition; Schizophrenia

Indexed keywords

5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; APOMORPHINE; BF 2649; CIPROXIFAN; DIZOCILPINE; HALOPERIDOL; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; METHAMPHETAMINE; PHENCYCLIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ATTENTION; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENTIATION; LEARNING; MALE; MEMORY; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; SENSORY GATING; STEREOTYPY;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BENZOFURANS; DIZOCILPINE MALEATE; DRUG INVERSE AGONISM; HALOPERIDOL; HISTAMINE ANTAGONISTS; IMIDAZOLES; INHIBITION (PSYCHOLOGY); MALE; METHAMPHETAMINE; MICE; PHENCYCLIDINE; PIPERIDINES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; STARTLE REACTION; STEREOTYPED BEHAVIOR;

EID: 77955663097     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1863-2     Document Type: Article

References (71)

1. Arai S, Takuma K, Mizoguchi H, Ibi D, Nagai T, Takahashi K, Kamei H, Nabeshima T, Yamada K (2008) Involvement of pallidotegmental neurons in methamphetamine-and MK-801-induced impairment of prepulse inhibition of the acoustic startle reflex in mice: reversal by GABAB receptor agonist baclofen. Neuropsychopharmacology 33:3164-3175
2. Arrang JM (2007) Histamine and schizophrenia. Int Rev Neurobiol 78:247-287
3. 3) of histamine receptor. Nature 302:832-837
4. 3-receptors. Nature 327:117-123
5. Arrang JM, Devaux B, Chodkiewicz JP, Schwartz JC (1988) H3-receptors control histamine release in human brain. J Neurochem 51:105-108
6. 3 receptor. Trends Pharmacol Sci 28:350-357
7. Auclair AL, Kleven MS, Besnard J, Depoortere R, Newman-Tancredi A (2006) Actions of novel antipsychotic agents on apomorphineinduced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology 31:1900-1909
8. Bakshi VP, Geyer MA (1998) Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J Neurosci 18:8394-8401
9. Bast T, Zhang W, Feldon J, White IM (2000) Effects of MK801 and neuroleptics on prepulse inhibition: re-examination in two strains of rats. Pharmacol Biochem Behav 67:647-658
10. Bortolato M, Frau R, Aru GN, Orru M, Gessa GL (2004) Baclofen reverses the reduction in prepulse inhibition of the acoustic startle response induced by dizocilpine, but not by apomorphine. Psychopharmacology (Berl) 171:322-330
11. Bortolato M, Frau R, Orru M, Bourov Y, Marrosu F, Mereu G, Devoto P, Gessa GL (2008) Antipsychotic-like properties of 5-alphareductase inhibitors. Neuropsychopharmacology 33:3146-3156
12. Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156:234-258
13. Braff D, Schork NJ, Gottesman II (2007) Endophenotyping schizophrenia. Am J Psychiatry 164:705-707
14. Brody SA, Conquet F, Geyer MA (2004) Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology (Berl) 172:187-195
15. 3 receptor antagonists thioperamide and ciproxifan. Behav Brain Res 153:69-76
16. 3 receptor antagonists reach out for the clinic. Drug Discov Today 10:1613-1627
17. Clapham J, Kilpatrick GJ (1994) Thioperamide, the selective histamine H3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. Eur J Pharmacol 259:107-114
18. Curzon P, Decker MW (1998) Effects of phencyclidine (PCP) and (+) MK-801 on sensorimotor gating in CD-1 mice. Prog Neuropsychopharmacol Biol Psychiatry 22:129-146
19. Davenas E, Rouleau A, Morisset S, Arrang JM (2008) Autoregulation of McA-RH7777 hepatoma cell proliferation by histamine H3 receptors. J Pharmacol Exp Ther 326:406-413
20. Dulawa SC, Geyer MA (1996) Psychopharmacology of prepulse inhibition in mice. Chin J Physiol 39:139-146
21. Elvevag B, Goldberg TE (2000) Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14:1-21
22. 3 receptor antagonist with drug-like properties. J Pharmacol Exp Ther 313:165-175
23. 3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol Interv 6 (77-88): 59
24. Faucard R, Armand V, Heron A, Cochois V, Schwartz JC, Arrang JM (2006) N-Methyl-D-aspartate receptor antagonists enhance histamine neuron activity in rodent brain. J Neurochem 98:1487-1496
25. Feifel D, Priebe K (1999) The effects of subchronic haloperidol on intact and dizocilpine-disrupted sensorimotor gating. Psychopharmacology (Berl) 146:175-179
26. Ferrada C, Ferre S, Casado V, Cortes A, Justinova Z, Barnes C, Canela EI, Goldberg SR, Leurs R, Lluis C, Franco R (2008) Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology 55:190-197
27. 3 receptor antagonist. J Pharmacol Exp Ther 313:176-190
28. Geyer M, Moghaddam B (2002) Animal models relevant to schizophrenia disorders. In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds) Neuropsychopharmacology: the fifth generation of progress. Lippincott Williams & Wilkins, Philadelphia, pp 689-701
29. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117-154
30. Haas H, Panula P (2003) The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 4:121-130
31. Haas HL, Sergeeva OA, Selbach O (2008) Histamine in the nervous system. Physiol Rev 88:1183-1241
32. 3 receptor antagonists/inverse agonists as antiobesity agents. Curr Opin Investig Drugs 4:1190-1197
33. 3 receptor ligands and neurological disease. Expert Opin Investig Drugs 13:1237-1248
34. Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, Schunack W, Levi R, Haas HL (1997) International union of pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 49:253-278
35. 35S] GTPgamma[S] binding in rat striatum: evidence for additive effects but lack of interactions. Biochem Pharmacol 73:1172-1181
36. 3 receptor modulation of haloperidol-induced c-fos expression in the striatum and nucleus accumbens. Neuroscience 112:427-438
37. Ito C, Onodera K, Sakurai E, Sato M, Watanabe T (1996) Effects of dopamine antagonists on neuronal histamine release in the striatum of rats subjected to acute and chronic treatments with methamphetamine. J Pharmacol Exp Ther 279:271-276
38. Kamei C (2001) Involvement of central histamine in amygdaloid kindled seizures in rats. Behav Brain Res 124:243-250 (Pubitemid 32964642)
39. Kapur S, Seeman P (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D (2) and serotonin 5-HT (2) receptors- implications for models of schizophrenia. Mol Psychiatry 7:837-844
40. Kargieman L, Santana N, Mengod G, Celada P, Artigas F (2007) Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad Sci USA 104:14843-14848
41. Keith VA, Mansbach RS, Geyer MA (1991) Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 30:557-566
42. Kellendonk C, Simpson EH, Kandel ER (2009) Modeling cognitive endophenotypes of schizophrenia in mice. Trends Neurosci 32:347-358
43. Kinney GG, Wilkinson LO, Saywell KL, Tricklebank MD (1999) Rat strain differences in the ability to disrupt sensorimotor gating are limited to the dopaminergic system, specific to prepulse inhibition, and unrelated to changes in startle amplitude or nucleus accumbens dopamine receptor sensitivity. J Neurosci 19:5644-5653
44. Leurs R, Bakker RA, Timmerman H, de Esch IJ (2005) The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 4:107-120
45. Leysen JE, Janssen PM, Schotte A, Luyten WH, Megens AA (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl) 112: S40-S54
46. Ligneau X, Lin J, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, Stark H, Elz S, Schunack W, Schwartz J (1998) Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther 287:658-666
47. Ligneau X, Landais L, Perrin D, Piriou J, Uguen M, Denis E, Robert P, Parmentier R, Anaclet C, Lin JS, Burban A, Arrang JM, Schwartz JC (2007a) Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem Pharmacol 73:1215-1224
48. 3 receptor: preclinical pharmacology. J Pharmacol Exp Ther 320:365-375
49. Lin JS (2000) Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 4:471-503
50. Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC (2008) An inverse agonist of the histamine H (3) receptor improves wakefulness in narcolepsy: studies in orexin-/-mice and patients. Neurobiol Dis 30:74-83
51. Mansbach RS, Carver J, Zorn SH (2001) Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone. Pharmacol Biochem Behav 69:535-542
52. Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, Schunack W, Ganellin CR, Schwartz JC, Arrang JM (2000) High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408:860-864
53. Morisset S, Pilon C, Tardivel-Lacombe J, Weinstein D, Rostene W, Betancur C, Sokoloff P, Schwartz JC, Arrang JM (2002) Acute and chronic effects of methamphetamine on tele-methylhistamine levels in mouse brain: selective involvement of the D (2) and not D (3) receptor. J Pharmacol Exp Ther 300:621-628
54. Okuda T, Ito Y, Nakagawa N, Hishinuma T, Tsukamoto H, Iwabuchi K, Watanabe T, Kitaichi K, Goto J, Yanai K (2004) Drug interaction between methamphetamine and antihistamines: behavioral changes and tissue concentrations of methamphetamine in rats. Eur J Pharmacol 505:135-144
55. Parmentier R, Anaclet C, Guhennec C, Brousseau E, Bricout D, Giboulot T, Bozyczko-Coyne D, Spiegel K, Ohtsu H, Williams M, Lin JS (2007) The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol 73:1157-1171
56. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 25:618-625
57. Paylor R, Crawley JN (1997) Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology (Berl) 132:169-180
58. Pillot C, Heron A, Cochois V, Tardivel-Lacombe J, Ligneau X, Schwartz JC, Arrang JM (2002a) A detailed mapping of the histamine H3 receptor and its gene transcripts in rat brain. Neuroscience 114:173-193
59. 3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat. J Neurosci 22:7272-7280
60. Pillot C, Heron A, Schwartz JC, Arrang JM (2003) Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum. Eur J Neurosci 17:307-314
61. Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ (1995) Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res 14:93-104
62. Ralph RJ, Caine SB (2005) Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. J Pharmacol Exp Ther 312:733-741
63. Ralph-Williams RJ, Lehmann-Masten V, Otero-Corchon V, Low MJ, Geyer MA (2002) Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci 22:9604-9611
64. Ralph-Williams RJ, Lehmann-Masten V, Geyer MA (2003) Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology 28:108-118
65. Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29-39
66. Rothman RB (1994) PCP site 2: a high affinity MK-801-insensitive phencyclidine binding site. Neurotoxicol Teratol 16:343-353
67. Ryu JH, Yanai K, Zhao XL, Watanabe T (1996) The effect of dopamine D1 receptor stimulation on the up-regulation of histamine H3-receptors following destruction of the ascending dopaminergic neurones. Br J Pharmacol 118:585-592
68. Southam E, Cilia J, Gartlon JE, Woolley ML, Lacroix LP, Jennings CA, Cluderay JE, Reavill C, Rourke C, Wilson DM, Dawson LA, Medhurst AD, Jones DN (2009) Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040. Psychopharmacology (Berl) 201:483-494
69. Toyota H, Dugovic C, Koehl M, Laposky AD, Weber C, Ngo K, Wu Y, Lee DH, Yanai K, Sakurai E, Watanabe T, Liu C, Chen J, Barbier AJ, Turek FW, Fung-Leung WP, Lovenberg TW (2002) Behavioral characterization of mice lacking histamine H (3) receptors. Mol Pharmacol 62:389-397
70. Weber M, Chang WL, Breier M, Ko D, Swerdlow NR (2008) Heritable strain differences in sensitivity to the startle gatingdisruptive effects of D2 but not D3 receptor stimulation. Behav Pharmacol 19:786-795
71. 3 receptor antagonists and antipsychotic drugs. Brain Res 1045:142-149